What constitutes the most cautious approach for a pregnant person with weak D type 4.0?

A recent CMAJ Practice article¹ on modern Rhesus (Rh) typing in transfusion and pregnancy and its associated correspondence² prompted a productive discussion on safe recommendations for pregnant patients with a weak D type 4.0 allele, originally described in 2000.³ The differing approaches^1,2 represent the personal views of the respective authors. Based on our review of 20 years’ worth of literature on this specialized topic, we have agreed on the following 5 statements:

1. No published case reports have documented adverse clinical effects, such as hemolysis, among pregnant people with weak D type 4.0 caused by an allo- or auto-anti–D.

2. Similarly, no published case reports have documented adverse clinical effects, such as anemia or jaundice, among fetuses or newborns caused by such a mother’s allo- or auto-anti–D.

3. No published evidence has shown that Rh immunoglobulin (RhIg) is clinically effective in an individual with weak D type 4.0 (e.g., for preventing anti-D formation); RhIg can cause a positive direct antiglobulin test, which does not imply clinical harm.

4. The weak D type 4.0 phenotype may be associated with a proportionately larger number of anti-D than most other weak D types.^4–6 The nature of these antibodies has not been well characterized (i.e., allo- v. auto-antibody). ⁶ A fraction of all people with a weak D type 4.0 are routinely typed as normal RhD-positive and do not receive RhIg.^3,7,8

5. The decision of whether or not to use RhIg or RhD-negative transfusion in such mothers should be based on national guidelines.⁹ Both approaches have been adopted by expert groups^2,6,8–10 and are considered safe. The decision may still depend on an individual patient’s circumstances. ¹¹ If providers are unsure, consultation with a transfusion medicine physician or perinatal immunohematology reference laboratory is recommended.^1,10